BG106119A - Тиазолидиндионово производно и използването му като антидиабетично средство - Google Patents

Тиазолидиндионово производно и използването му като антидиабетично средство

Info

Publication number
BG106119A
BG106119A BG106119A BG10611901A BG106119A BG 106119 A BG106119 A BG 106119A BG 106119 A BG106119 A BG 106119A BG 10611901 A BG10611901 A BG 10611901A BG 106119 A BG106119 A BG 106119A
Authority
BG
Bulgaria
Prior art keywords
provides
compound
containing peaks
listed
description
Prior art date
Application number
BG106119A
Other languages
English (en)
Other versions
BG65427B1 (bg
Inventor
Paul Blackler
Robert Giles
Michael Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG106119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BG106119A publication Critical patent/BG106119A/bg
Publication of BG65427B1 publication Critical patent/BG65427B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретението се отнася до полиморфна форма на 5-[4-[2-(N-метил-N- (2-пиридил) амино)етокси] бензил] тиазолидин-2,4-дион, сол с малеиновата киселина(полиморфа), която има инфрачервен спектър, съдържащ пикове при 1360, 1326, 1241, 714 и 669 cm-1, и/или Раманов спектър, съдържащ пикове при 1581, 768, 670, 271 и 226 cm-1, и/или спектър на ядрения магнитен резонанс в твърдо състояние, съдържащ пикове на химически отмествания, както е посочено в описанието, и/или рентгенова прахова дифрактограма (XRPD), съдържаща пикове, както е посочено в описанието. Изобретението се отнася и до метод за получаване на това съединение, до фармацевтичен състав, който го съдържа, и до използването му в медицината.
BG106119A 1999-04-23 2001-11-20 Тиазолидиново производно, метод за получаването му, фармацевтичен състав и използването му за лечение на диабет BG65427B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical

Publications (2)

Publication Number Publication Date
BG106119A true BG106119A (bg) 2002-05-31
BG65427B1 BG65427B1 (bg) 2008-07-31

Family

ID=26315460

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106119A BG65427B1 (bg) 1999-04-23 2001-11-20 Тиазолидиново производно, метод за получаването му, фармацевтичен състав и използването му за лечение на диабет

Country Status (40)

Country Link
US (2) US6815457B1 (bg)
EP (3) EP1903043A1 (bg)
JP (1) JP2002543075A (bg)
KR (1) KR100744359B1 (bg)
CN (1) CN1208335C (bg)
AP (1) AP1495A (bg)
AR (2) AR023568A1 (bg)
AT (2) ATE382046T1 (bg)
AU (1) AU765498B2 (bg)
BG (1) BG65427B1 (bg)
BR (1) BR0009934A (bg)
CA (1) CA2370258A1 (bg)
CO (1) CO5170424A1 (bg)
CY (1) CY1107238T1 (bg)
CZ (1) CZ20013799A3 (bg)
DE (2) DE60037602T2 (bg)
DK (2) DK1173434T3 (bg)
DZ (1) DZ3155A1 (bg)
EA (1) EA004534B1 (bg)
ES (2) ES2298327T3 (bg)
HK (2) HK1045154B (bg)
HR (1) HRP20010773B1 (bg)
HU (1) HUP0200929A3 (bg)
IL (1) IL146110A0 (bg)
MA (1) MA26785A1 (bg)
MX (1) MXPA01010820A (bg)
MY (1) MY128007A (bg)
NO (1) NO320589B1 (bg)
NZ (1) NZ515163A (bg)
OA (1) OA11871A (bg)
PE (1) PE20010040A1 (bg)
PL (1) PL351686A1 (bg)
PT (2) PT1284268E (bg)
RS (1) RS50114B (bg)
SK (1) SK286423B6 (bg)
TR (1) TR200103061T2 (bg)
TW (1) TW591027B (bg)
UA (1) UA67843C2 (bg)
UY (1) UY26120A1 (bg)
WO (1) WO2000064892A2 (bg)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
OA11871A (en) 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
ES2203453T3 (es) * 1999-04-23 2004-04-16 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
EP1322647A1 (en) * 2000-09-26 2003-07-02 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt and process for their preparation
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
SG47100A1 (en) 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
SK179499A3 (en) 1997-06-18 2000-11-07 Smithkline Beecham Plc The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
AU8539298A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
AU8539398A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PE20010045A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
ES2203453T3 (es) 1999-04-23 2004-04-16 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
OA11871A (en) 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
EP1322647A1 (en) 2000-09-26 2003-07-02 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt and process for their preparation

Also Published As

Publication number Publication date
OA11871A (en) 2006-03-27
JP2002543075A (ja) 2002-12-17
HRP20010773B1 (en) 2005-06-30
HUP0200929A2 (en) 2002-08-28
DE60004658D1 (de) 2003-09-25
MXPA01010820A (es) 2002-06-04
YU75201A (sh) 2004-09-03
DE60037602T2 (de) 2009-01-08
PT1284268E (pt) 2008-03-10
WO2000064892A2 (en) 2000-11-02
WO2000064892A3 (en) 2001-01-25
SK14912001A3 (sk) 2002-02-05
HK1055293A1 (en) 2004-01-02
RS50114B (sr) 2009-03-25
KR20020028873A (ko) 2002-04-17
HRP20010773A2 (en) 2002-10-31
EP1173434A2 (en) 2002-01-23
PL351686A1 (en) 2003-06-02
PE20010040A1 (es) 2001-03-10
BR0009934A (pt) 2002-06-04
DK1284268T3 (da) 2008-04-28
NO20015149L (no) 2001-12-17
EP1284268A1 (en) 2003-02-19
ES2204557T3 (es) 2004-05-01
TR200103061T2 (tr) 2002-05-21
CZ20013799A3 (cs) 2002-04-17
KR100744359B1 (ko) 2007-07-30
CA2370258A1 (en) 2000-11-02
ATE382046T1 (de) 2008-01-15
AR023564A1 (es) 2002-09-04
EA004534B1 (ru) 2004-06-24
HK1045154A1 (en) 2002-11-15
CO5170424A1 (es) 2002-06-27
DE60004658T2 (de) 2004-06-24
CN1208335C (zh) 2005-06-29
MA26785A1 (fr) 2004-12-20
DK1173434T3 (da) 2003-12-08
SK286423B6 (sk) 2008-09-05
NO20015149D0 (no) 2001-10-22
ES2298327T3 (es) 2008-05-16
IL146110A0 (en) 2002-07-25
DE60037602D1 (de) 2008-02-07
AP1495A (en) 2005-11-30
PT1173434E (pt) 2003-12-31
UY26120A1 (es) 2000-12-29
MY128007A (en) 2007-01-31
UA67843C2 (uk) 2004-07-15
EP1173434B1 (en) 2003-08-20
TW591027B (en) 2004-06-11
AR023568A1 (es) 2002-09-04
NZ515163A (en) 2004-02-27
US20040092555A1 (en) 2004-05-13
EP1903043A1 (en) 2008-03-26
DZ3155A1 (fr) 2000-11-02
US6815457B1 (en) 2004-11-09
EA200101119A1 (ru) 2002-04-25
CY1107238T1 (el) 2012-11-21
HUP0200929A3 (en) 2004-03-29
CN1355801A (zh) 2002-06-26
HK1045154B (zh) 2004-06-25
BG65427B1 (bg) 2008-07-31
AU765498B2 (en) 2003-09-18
EP1284268B1 (en) 2007-12-26
NO320589B1 (no) 2005-12-27
AU4130600A (en) 2000-11-10
ATE247653T1 (de) 2003-09-15

Similar Documents

Publication Publication Date Title
BG106119A (bg) Тиазолидиндионово производно и използването му като антидиабетично средство
NZ515168A (en) Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
BG104606A (bg) Заместено производно на тиазолидиндион, метод за неговото получаване и фармацевтичното му използване
MY135612A (en) Novel pharmaceutical
AP1607A (en) Thiazolidinedione derivative and its use as antidiabetic.
HUP0300158A2 (en) Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them
AP1441A (en) Hydrate of 5- [4-{2-(N-methlyl-N-(2-pyridil) amino) ethoxy} benzyl] thiazolidine-2,4-dione maleic acid salt.
MY126034A (en) Thiazolidinedione derivative and its use as antidiabetic
BG106120A (bg) Тиазолидиндионово производно и изролзването му като антидиабетично средство
ECSP003438A (es) Nuevos compuestos
ECSP003436A (es) Nuevos compuestos
ECSP003437A (es) Nuevos compuestos
ECSP982780A (es) Nuevo producto farmaceutico proceso para su preparacion y su uso en medicina